This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burdelya, L. Articles by Yu, H. Search for Related Content PubMed PubMed Citation Articles by Burdelya, L. Articles by Yu, H.

Immunology Program [L. B., H. Y.], Molecular Oncology Program [R. C-F., L. B. M., R. J.], Clinical Investigations Program [F. C., E. S., D. C., W. S. D.], and Drug Discovery Program [J. S., S. S.], H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, and Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, 91904, Israel [A. L.]

Constitutive activation of Janus kinases (JAKs) and signal transducers and activators of transcription (STAT) occurs at very high frequency in various hematopoietic malignancies and solid tumors. It has been demonstrated that the tyrosine kinase inhibitor, AG-490, selectively blocks JAK activity and completely eliminates leukemia cells in a severe combined immunodeficient (SCID) mouse model. Because many cytokines, including interleukin (IL)-12, have been shown to signal through JAK/STAT pathways, AG-490 may inhibit cytokine-based cancer therapy. In this study, we evaluated the effects of AG-490 on IL-12 functional signaling and IL-12-mediated antitumor response in vivo. Previous studies have established the critical roles of macrophages and IFN- in mediating IL-12-induced antitumor effects. Our results show that in vivo administration of AG-490 causes tumor cell apoptosis but does not inhibit IL-12-mediated macrophage activation and IFN- production by lymphocytes. Furthermore, our data indicate that combined therapy with AG-490 and IL-12-induces greater antitumor effects than either agent alone in a murine myeloma tumor model. These results suggest that JAK/STAT inhibitors deserve further investigation for use with IL-12 therapy in treating human cancers with elevated JAK/STAT activity.

This article has been cited by other articles:

				S. Verstovsek, T. Manshouri, A. Quintas-Cardama, D. Harris, J. Cortes, F. J. Giles, H. Kantarjian, W. Priebe, and Z. Estrov WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation Clin. Cancer Res., February 1, 2008; 14(3): 788 - 796. [Abstract] [Full Text] [PDF]

				N. K. Saxena, P. M. Vertino, F. A. Anania, and D. Sharma Leptin-induced Growth Stimulation of Breast Cancer Cells Involves Recruitment of Histone Acetyltransferases and Mediator Complex to CYCLIN D1 Promoter via Activation of Stat3 J. Biol. Chem., May 4, 2007; 282(18): 13316 - 13325. [Abstract] [Full Text] [PDF]

				A. Levitzki Signal Transduction Therapy of Cancer from Concept to Clinic: Promises and Hurdles Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 45 - 48. [Full Text] [PDF]

				M. Samardzija, A. Wenzel, S. Aufenberg, M. Thiersch, C. Reme, and C. Grimm Differential role of Jak-STAT signaling in retinal degenerations FASEB J, November 1, 2006; 20(13): 2411 - 2413. [Abstract] [Full Text] [PDF]

				A. Ferrand, A. Kowalski-Chauvel, C. Bertrand, C. Escrieut, A. Mathieu, G. Portolan, L. Pradayrol, D. Fourmy, M. Dufresne, and C. Seva A Novel Mechanism for JAK2 Activation by a G Protein-coupled Receptor, the CCK2R: IMPLICATION OF THIS SIGNALING PATHWAY IN PANCREATIC TUMOR MODELS J. Biol. Chem., March 18, 2005; 280(11): 10710 - 10715. [Abstract] [Full Text] [PDF]

				P. Boutet, D. Boulanger, L. Gillet, A. Vanderplasschen, R. Closset, F. Bureau, and P. Lekeux Delayed Neutrophil Apoptosis in Bovine Subclinical Mastitis J Dairy Sci, December 1, 2004; 87(12): 4104 - 4114. [Abstract] [Full Text] [PDF]

				N. Jing, Y. Li, W. Xiong, W. Sha, L. Jing, and D. J. Tweardy G-Quartet Oligonucleotides: A New Class of Signal Transducer and Activator of Transcription 3 Inhibitors That Suppresses Growth of Prostate and Breast Tumors through Induction of Apoptosis Cancer Res., September 15, 2004; 64(18): 6603 - 6609. [Abstract] [Full Text] [PDF]

				D. E. Spaner Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells J. Leukoc. Biol., August 1, 2004; 76(2): 338 - 351. [Abstract] [Full Text] [PDF]